ITRM
Iterum Therapeutics plc
1W: +3.2%
1M: -25.7%
3M: -48.4%
YTD: -44.0%
1Y: -87.5%
3Y: -83.2%
5Y: -99.3%
$0.04
-0.14 (-79.77%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.9M
52W Range0.0271-1.5
Volume36,879,075
Avg Volume1,094,132
Beta3.01
Dividend—
Analyst Ratings
Company Info
CEOCorey N. Fishman
Employees9
SectorHealthcare
IndustryBiotechnology
IPO Date2018-05-25
Websiteiterumtx.com
Fitzwilliam Court
Dublin 2
IE
Dublin 2
IE
353 1 669 4820
About Iterum Therapeutics plc
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Latest News
12 Health Care Stocks Moving In Friday's Intraday Session
Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Update
Iterum Therapeutics $ITRM – Nasdaq Appeal & ORLYNVAH. Survival or Buyout?
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dunne Michael W. | P-Purchase | 6,000 | $0.37 | 2025-11-18 |
| Dunne Michael W. | P-Purchase | 15,000 | $0.72 | 2025-08-08 |
| Coyne Christine | A-Award | 200,000 | $0.97 | 2025-07-01 |
| Coyne Christine | 0 | — | 2025-07-01 | |
| Whalen Joseph John | 0 | — | 2025-03-10 |